Lexicon Pharmaceuticals to Present at ThinkEquity ThinkClinic
September 27 2007 - 4:00PM
PR Newswire (US)
THE WOODLANDS, Texas, Sept. 27 /PRNewswire-FirstCall/ -- Lexicon
Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Brian P.
Zambrowicz, Ph.D., Lexicon's executive vice president and chief
scientific officer, will present at the forum on Alzheimer's
Disease and Cognitive Disorders at ThinkEquity Partners LLC's
ThinkClinic at The Pierre in New York, New York on Thursday,
October 4, 2007 at 12:30 p.m. Eastern Time. A live webcast of
Lexicon's presentation may be accessed on its corporate website at
http://www.lexpharma.com/. An archived version of the webcast will
be available on the website through October 10, 2007. About Lexicon
Lexicon is a biopharmaceutical company focused on the discovery and
development of breakthrough treatments for human disease. Lexicon
currently has clinical programs underway for such areas of major
unmet medical need as irritable bowel syndrome and cognitive
disorders. The company has used its proprietary gene knockout
technology to discover more than 100 promising drug targets and
create an extensive pipeline of clinical and preclinical programs
in the therapeutic areas of diabetes and obesity, cardiovascular
disease, psychiatric and neurological disorders, cancer, immune
system disorders and ophthalmic disease. To advance the development
and commercialization of its programs, Lexicon is working both
independently and through collaborators including Bristol-Myers
Squibb Company, Genentech, Inc. and N.V. Organon. For additional
information about Lexicon and its programs, please visit
http://www.lexpharma.com/. Safe Harbor Statement This press release
contains "forward-looking statements," including statements
relating to Lexicon's growth and future operating results,
discovery and development of products, strategic alliances and
intellectual property, as well as other matters that are not
historical facts or information. All forward-looking statements are
based on management's current assumptions and expectations and
involve risks, uncertainties and other important factors that may
cause Lexicon's actual results to be materially different from any
future results expressed or implied by such forward-looking
statements. Information identifying such important factors is
contained under "Factors Affecting Forward-Looking Statements" and
"Risk Factors" in Lexicon's annual report on Form 10-K for the year
ended December 31, 2006, as filed with the Securities and Exchange
Commission. Lexicon undertakes no obligation to update or revise
any such forward-looking statements, whether as a result of new
information, future events or otherwise. DATASOURCE: Lexicon
Pharmaceuticals, Inc. CONTACT: Arti Allam, Corporate Communications
Associate, +1-281-863-3738, , or Julia P. Gregory, Executive Vice
President and Chief Financial Officer, +1-281-863-3000, , both of
Lexicon Pharmaceuticals, Inc. Web site: http://www.lexpharma.com/
Copyright
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024